$19.63 -$0.63 (-3.1%)

04:15 PM EST on 01/17/20

Invitae (NYSE:NVTA)

CAPS Rating: 4 out of 5

Current Price $19.63 Mkt Cap $1.9B
Open $0.00 P/E Ratio 0.00
Prev. Close $19.63 Div. (Yield) $0.00 (0.0%)
Daily Range $0.00 - $0.00 Volume 504,222
52-Wk Range $15.61 - $20.40 Avg. Daily Vol. 1,854,270


How do you think NYSE:NVTA will perform against the market?

Add Stock to CAPS Watchlist

All Players

108 Outperform
5 Underperform

All-Star Players

33 Outperform
5 Underperform

Wall Street

0 Outperform
0 Underperform

Top NYSE:NVTA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

MarkFitzFool (57.76)
Submitted May 12, 2019

Invitae is likely going to become the dominant player, Leader and Top Dog in the field of genetic testing and personalized medicine. This is NOT just another diagnostics company like Quest. This is NOT an Ancestry.com or a 23andMe. The IS a company… More

TSIF (99.97)
Submitted March 29, 2016

Today's ramp (22% at print) after moderately "good" news demonstrates a short covering action. While this type of price action may span several days, (as shorts re-upp, re-cover, and speculators and day traders join in), they are not sustainable.The… More



Fools bullish on NYSE:NVTA are also bullish on:

Fools bearish on NYSE:NVTA are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about NVTA.


Member Avatar mfoolid (67.13) Submitted: 12/15/2019 8:33:10 PM : Outperform Start Price: $16.94 NYSE:NVTA Score: +11.93

RS 2020 WAIT FOR $21.45


Member Avatar Capitalism (86.10) Submitted: 11/18/2019 1:40:18 PM : Underperform Start Price: $18.26 NYSE:NVTA Score: -1.16

Akram's Razor short pick


Member Avatar MarkFitzFool (57.76) Submitted: 5/12/2019 6:39:46 PM : Outperform Start Price: $19.42 NYSE:NVTA Score: -16.46

Invitae is likely going to become the dominant player, Leader and Top Dog in the field of genetic testing and personalized medicine. This is NOT just another diagnostics company like Quest. This is NOT an Ancestry.com or a 23andMe. The IS a company that does profoundly-deep, clinically-relevant genetic tests that bio pharma companies want to use in their research and clinical trials, that academic labs want to use in their research, and that doctors want to use in order to give their patients the best possible treatments. The dawn of the era of personalized medicine is upon us. Many doctors all over the world are already having their patients get genetic tests - looking for SNPs, looking for dominant vs. recessive genes, looking for mutations - in order to provide them with the best possible therapies (different medications/therapies have different efficacies for different genetic profiles). Not only does Invitae partner with bio pharma and academia, they are now going direct-to-consumer. Think comprehensive prenatal screens prior to pregnancy, think people without a significant family history of disease getting tested for the potential for cardiovascular disease, cancer, etc. (preventative genetic testing), think cutting-edge diagnostics for everything from eye diseases and metabolic disorders to dermatological and immune disorders. This is Invitae! They also employ machine-learning and AI. The more data they get, the better and more sophisticated their diagnostics get. It's a continuous cycle that will only keep growing. Invitae is set to be able to deliver genetic tests cheaper, more comprehensive, more cutting-edge, and more of higher quality than any other player in this space. They are, in fact transforming an existing market, and in the process creating a new one. The Street reacted badly to their recent quarter due to things like cash burn, one-time write-offs that weren't foreseen perfectly, revenue misses, etc. However, their 2020 guidance is amazing! They envision ~ 100% growth! (That's aspirational, official guidance will be given in January) Invitae is in it for the long-haul. This company wants investors who can see the forest for the trees. They don't think short-term. They don't care about short-term. They have a significant moat, and The Street doesn't see that yet. The Street is wrong. In the not-too-distant future it will become the norm for everyone to have their genomes sequenced/genetic screens done. This will not only happen after a severe disease is diagnosed, rather your genome will be the foundation for your preventative health, your treatments, everything. Invitae will lead the way. Mark my words.


Find the members with the highest scoring picks in NVTA.

Score Leader


willkmad (68.62) Score: +274.13

The Score Leader is the player with the highest score across all their picks in NVTA.

Member Name Member
Call Time
Score Commentary
willkmad 68.62 4/2/2018 Outperform 5Y $4.87 +303.08% +28.95% +274.13 0 Comment
Usualsspct 94.41 5/2/2018 Outperform 5Y $5.51 +256.26% +25.38% +230.88 0 Comment
Wamwaura 94.67 2/13/2018 Outperform 5Y $5.51 +256.26% +25.67% +230.59 0 Comment
starreyeyed 64.06 4/13/2018 Outperform 5Y $5.59 +251.16% +24.14% +227.03 0 Comment
dcrednek 70.80 4/16/2018 Outperform 5Y $5.69 +244.99% +24.33% +220.67 0 Comment
manary 87.50 4/27/2018 Outperform 5Y $5.75 +241.39% +24.33% +217.07 0 Comment
JohnAnthony02 < 20 2/13/2018 Outperform 3Y $5.95 +229.92% +25.75% +204.16 0 Comment
BestInvest < 20 3/27/2018 Outperform 5Y $5.98 +228.26% +25.13% +203.13 0 Comment
mrmrmrj 52.28 2/13/2018 Outperform 5Y $6.09 +222.33% +24.90% +197.44 0 Comment
onehitter 88.13 2/5/2018 Outperform 5Y $6.42 +205.76% +21.39% +184.37 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NVTA.